|
|
News Breaks | | | | January 8, 2013 | | 06:32 EDT |  | GTXI | FDA designates GTx's enobosarm as Fast Track development program
GTx announced that the FDA has designated enobosarm, or GTx-024, for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer as a Fast Track development program. Fast Track status is a process designed by FDA to facilitate the development and expedite the review of new drug candidates that are intended to treat serious diseases and have the potential to fill an unmet medical need. With a Fast Track designation, there is an increased possibility for a priority review of a new drug application, or, NDA, filed for the drug candidate and more opportunity for more frequent interactions with the FDA both prior to and following the filing of a NDA. | |
|
News For GTXI From The Last 14 Days Check below for free stories on GTXI the last two weeks. |
|
|
| There are no results for GTXI |
|
|
|
|
|
|
